AMRN
Amarin·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 2
Bearish signal 3
Ample Liquidity
High Gross Profit Margin
EPS Below Expectations
Revenue Below Expectations
Consecutive Revenue Decline
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About AMRN
Amarin Corporation Plc
A biopharmaceutical company that develops and commercializes cardiovascular and lipid-focused therapeutics
Pharmaceutical
03/01/1989
04/02/1993
NASDAQ Stock Exchange
275
12-31
Depository Receipts (Ordinary Shares)
Iconic Offices, The Greenway, Block C Ardilaun Court, 112-114 St Stephens Green, Dublin 2, Ireland
--
Amarin Corporation Plc was incorporated in the United Kingdom on March 1, 1989. The Company is a pharmaceutical company focused on the commercialization and development of therapies that improve cardiovascular or cardiovascular health and reduce cardiovascular risk. The company's commercialized product, VASCEPA, was first approved by the U.S., or the U.S., the Food and Drug Administration, or the U.S. FDA, as a dietary supplement to reduce triglyceride or TG levels in adults with severe (≥ 500 mg/dL) hypertriglyceridemia, or marine indications.
Earnings Call
Q1/2025
Estimate EPS-0.4
Actual EPS-0.02
Estimate Revenue50.75M
Actual Revenue42.02M
Amarin's Q1 2025 Earnings Call: Contradictions in Global Revenue Trends and U.S. Pricing Pressures
May 07,2025 11:02
Earnings Decrypt
Earnings Decrypt
Q2/2025
Estimate EPS-0.61
Actual EPS-0.03
Estimate Revenue53.76M
Actual Revenue72.74M
Amarin's Q2 2025: Key Contradictions in U.S. Market Share, International Growth, and Pricing Trends
Jul 30,2025 02:16
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
AMRN has released its 2025 Q3 earnings. EPS was reported at -0.4, versus the expected 0, missing expectations. The chart below visualizes how AMRN has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
AMRN has released its 2025 Q3 earnings report, with revenue of 49.67M, reflecting a YoY change of 17.43%, and net profit of -7.74M, showing a YoY change of 69.21%. The Sankey diagram below clearly presents AMRN's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
